TD Cowen initiates NervGen Pharma with a Buy rating, projecting $1.1B in peak sales for its lead asset NVG-291.
NervGen Pharma (NGEN) shares rose after TD Cowen initiated coverage with a Buy rating, forecasting $1.1B in peak sales for its lead asset NVG-291. The injectable therapy is expected to enter a registrational study in mid-2026.
The initiation follows NervGen’s focus on developing treatments for nervous system damage. TD Cowen’s projection highlights confidence in the asset’s commercial potential, though no prior consensus estimates were disclosed.
Shares traded higher on the news, reflecting investor optimism about the biotech’s pipeline.